Aeglea Aeglea
  • Contact
  • Privacy Policy
  • Term of Use
  • Purchase Terms
  • COVID-19 Statement
  • Company
    • About
    • Leadership
    • Partnering
    • Contact
  • Focus
    • Enzyme Therapeutics
    • Rare Metabolic Disease
    • Publications
  • Programs
    • Pipeline
    • Pegtarviliase
    • Pegzilarginase
    • Clinical Trials
  • Careers
    • Job Openings
    • Life at Aeglea
  • Investors & Media
    • Company Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financials
      • Quarterly Reports
      • Annual Reports and Proxy
      • SEC Filings
    • Corporate Governance
      • Governance Documents
      • Management
      • Board of Directors
      • Committee Composition
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Patients & Families
    • Overview
    • Homocystinuria
    • Arginase 1 Deficiency
    • Diet & Nutrition
    • Clinical Trials FAQs
Select Page

ARG1 Variants in Arginase 1 Deficiency: Genetic Characterization of Participants in the Pegzilarginase Clinical Trials

by Tom Haan | Oct 31, 2022

The role of control of arginine levels in arginase 1 deficiency

by Tom Haan | Sep 11, 2022

Pegzilarginase Efficacy in Arginase 1 Deficiency: Results of the PEACE Pivotal Phase 3 Trial

by Tom Haan | Aug 25, 2022

Safety and Tolerability of Pegzilarginase for Arginase 1 Deficiency in the PEACE Pivotal Phase 3 Clinical Trial

by Tom Haan | Aug 25, 2022

Epidemiology, methods of diagnosis, and clinical management of patients with arginase 1 deficiency (ARG1-D): A systematic review

by Tom Haan | Aug 15, 2022

Health Care Resource Utilization in the Management of Patients with Arginase 1 Deficiency in the US: A Retrospective, Observational, Claims Database Study

by Tom Haan | Jun 22, 2022

Pegzilarginase in Arginase 1 Deficiency: Results of the PEACE Pivotal Phase 3 Clinical Trial

by Tom Haan | Apr 11, 2022

Pre-Analytical Considerations Are Important In The Pharmacological Assessment Of Enzyme Therapeutics

by Tom Haan | Mar 15, 2022

Natural history of arginase 1 deficiency and the unmet needs of patients: A systematic review of case reports

by Tom Haan | Mar 10, 2022

Arginase 1 Deficiency: Using Genetic Databases as a Tool to Establish Global Prevalence

by Tom Haan | Mar 10, 2022

Treatment Outcomes with Pegzilarginase Compared with Standard of Care for Patients with Arginase 1 Deficiency

by Tom Haan | Dec 25, 2021

Diagnosis of Arginase 1 Deficiency in a Patient With Cerebral Palsy

by Tom Haan | Nov 15, 2021

Diagnosis and Long Term Treatment of Arginase 1 Deficiency

by Tom Haan | Nov 15, 2021

Arginine: The Key Driver of Pathophysiology and Progression in Arginase 1 Deficiency

by Tom Haan | Nov 15, 2021

Patient Characteristics in the Pivotal Phase 3 PEACE Trial of Pegzilarginase Human Enzyme Therapy for Arginase 1 Deficiency

by Tom Haan | Nov 15, 2021

Management and Progression of Arginase 1 Deficiency Over 2 Decades of Follow Up

by Tom Haan | Nov 15, 2021

Arginase 1 Deficiency (ARG1-D) Presenting With Clotting Abnormalities

by Tom Haan | Nov 15, 2021

Gait Improvement in Pegzilarginase-treated Patients with Arginase 1 Deficiency: A Blinded Kinematic Analysis

by Tom Haan | Sep 15, 2021

Clinical effect and safety profile of pegzilarginase in patients with arginase 1 deficiency

by Tom Haan | Jul 14, 2021

Arginase 1 Deficiency (ARG1-D): A Systematic Literature Review

by Tom Haan | Jan 15, 2021

12>>

Recent Comments

    Company

    • About
    • Leadership
    • Partnering
    • Contact

    Focus

    • Enzyme Therapeutics
    • Rare Metabolic Disease
    • Publications

    Programs

    • Pipeline
    • Pegtarviliase
    • Pegzilarginase
    • Clinical Trials

    Careers

    • Job Openings
    • Life at Aeglea

    Investors & Media

    • Company Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Financials
    • Corporate Governance
    • Resources

    Patients & Families

    • Overview
    • Homocystinuria
    • Arginase 1 Deficiency
    • Diet & Nutrition
    • Clinical Trials FAQs
    © 2023 Aeglea BioTherapeutics. Privacy Policy Terms of Use Purchase Terms COVID-19 Statement
    • Welcome
    • About ARG1-D
    • Diagnosing ARG1-D
    • Managing ARG1-D
    • Patient Advocacy
    • Connect